The clinical trial to study a new drug, AP-2.
MOLEFY-AP-2-2025-PHA
Phase 1 other active
Quick answer
The clinical trial to study a new drug, AP-2. for ALS and related disorders like frontotemporal dementia and Alexander disease. is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- ALS and related disorders like frontotemporal dementia and Alexander disease.
- Phase
- Phase 1
- Modality
- other
- Status
- active